FDA Warning Letters Released The Weeks Of Nov. 18 and 25
This article was originally published in The Gray Sheet
Executive Summary
Agency issues seven device-related warning letters, including one ordering 23andMe to halt marketing of its high-profile direct-to-consumer genetic testing service until the test gains regulatory approval.